FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma By Ogkologos - March 25, 2026 216 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer MOST POPULAR Man Spent 20 Years Tracking Down And Buying His Late Mother’s... October 30, 2021 A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials May 7, 2019 Sacituzumab Govitecan Demonstrates a Relatively High ORR with Rapid Responses in... September 16, 2024 Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic... June 26, 2021 Load more HOT NEWS 4 Tips from Oncology Dietitians for Healthier Eating During Cancer Study Says Exercise Combats Side Effects of Chemo and Other Meds... PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients... Farmer With Stage IV Cancer Is Too Sick To Harvest Crops...
